Literature DB >> 7898066

Differential inhibition of platelet aggregation and calcium mobilization by nitroglycerin and stabilized nitric oxide.

M Amano1, M Takahashi, T Kosaka, M Kinoshita.   

Abstract

We compared the mechanisms of the antiplatelet effects of nitroglycerin (NTG) and stabilized nitric oxide (NO). Stabilized NO was in the form of S-nitrosothiols [S-nitroso-albumin (S-NO-Alb) and S-nitrosocaptopril (S-NO-Cap)] or heme-NO [sodium nitro-prusside (SNP)]. The molecular structure of S-NO-Cap was confirmed by mass spectrometry. NTG, SNP, S-NO-Alb, and S-NO-Cap inhibited ADP-induced platelet aggregation dose dependently. The inhibitory IC50 value was 109 microM for NTG, 0.98 microM for SNP, 2.99 microM for S-NO-Alb, and 2.5 microM for S-NO-Cap. NTG (200 microM) released 15.4 microM nitrite anion into platelet-rich plasma (PRP) after 60-min incubation, to which platelets contributed 5.4 microM. On the other hand, SNP and S-NO-Cap released undetectable amounts of NO2- when incubated in either PRP or platelet-poor plasma (PPP). The platelet cytosolic calcium ion (Ca2+) concentration was measured fluorometrically in Fura-2-loaded gel-filtered platelets. Thrombin-induced Ca2+ mobilization was significantly inhibited by 10 microM NTG, SNP, S-NO-Alb, and S-NO-Cap, whereas resting Ca2+ was unaltered. Ca2+ mobilization was inhibited 28.6% by NTG, 91.9% by SNP, 90.0% by S-NO-Alb, and 92.7% by S-NO-Cap. These results demonstrate that NTG is an exogenous donor of NO, but releases it only slowly. On the other hand, SNP and S-nitrosothiols inhibited platelet aggregation by the action of stabilized NO incorporated in their structure and did not release NO. NTG and stabilized NO shared a common mechanism of antiplatelet activity, which involved inhibition of calcium mobilization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7898066     DOI: 10.1097/00005344-199424060-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Influence of authentic nitric oxide on basal cytosolic [Ca2+] and Ca2+ release from internal stores in human platelets.

Authors:  K H Le Quan Sang; F Lantoine; M A Devynck
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

2.  In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor.

Authors:  L Jia; H Wong
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.

Authors:  Kerry L Homer; Janet C Wanstall
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

4.  Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initiating metastatic cascade.

Authors:  Yusheng Lu; Ting Yu; Haiyan Liang; Jichuang Wang; Jingjing Xie; Jingwei Shao; Yu Gao; Suhong Yu; Shuming Chen; Lie Wang; Lee Jia
Journal:  Sci Rep       Date:  2014-03-11       Impact factor: 4.379

5.  Temporal inhibition of mouse mammary gland cancer metastasis by CORM-A1 and DETA/NO combination therapy.

Authors:  Kseniia Porshneva; Diana Papiernik; Mateusz Psurski; Agnieszka Łupicka-Słowik; Rafał Matkowski; Marcin Ekiert; Marcin Nowak; Joanna Jarosz; Joanna Banach; Magdalena Milczarek; Tomasz M Goszczyński; Marcin Sieńczyk; Joanna Wietrzyk
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.